...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Necessary Expansion of the Management Board at Rentschler Biotechnologie GmbH

| Print |
Wednesday, 07 November 2012 13:45 (UTC + 1)

Rentschler_Logo_new

Laupheim, Germany, November 7, 2012 / B3C newswire / - The family-owned business based in Laupheim has expanded its management board. As a contract manufacturing organization, Rentschler Biotechnologie GmbH performs research on, develops, and produces biologicals for its international clientele. 

Reiner Winkelbauer, who has been the company’s Commercial Manager for the past four years, was appointed Managing Director of Finances. He was previously the Controlling and Chief Financial Officer of AEG in Ulm and later became the Commercial Manager at EADS also in Ulm.

Since September 1, 2012, Thomas Siklosi has strengthened the management board in the GMP Operations area. Before he started working at Rentschler Biotechnologie as manager of the Active Substance Department in 1984, Siklosi worked for Boehringer Mannheim for 10 years. In 2008, he took over the management of GMP Operations at Rentschler.

In the future, Siklosi will also be responsible for the “operational excellence” program at Rentschler that will focus on customer needs and on optimizing quality and efficiency. Starting from November 1, 2012, he will be actively supported by Luca Dellacroce, the “new face” in Rentschler’s management board. In the past, Dellacroce worked for notable companies such as Motorola and Nokia in process optimization.

Frank Ternes will also be a new addition to the management level at Rentschler beginning February 1, 2013. After 25 years at Boehringer Ingelheim where he last served as Senior Vice President of Biopharmaceutical Contract Manufacturing, Ternes will now become Managing Director of Sales at Rentschler.

Dr. Nikolaus F. Rentschler, CEO and owner, explains the necessary changes that led to a larger management board as follows:

“To accommodate the rapid growth of the company during the past 10 years, the management board had to also “grow.” Internal processes must be constantly reconsidered and optimized in order to serve our customers even better and more efficiently. For this reason, I decided to implement the necessary steps to achieve process optimization in my company. I wish Messrs. Winkelbauer, Siklosi, Dellacroce, and Ternes the strength and fortitude, as well as the determination and perseverance to act in the interests and for the success of my company.”

 
About Rentschler
Rentschler Biotechnologie GmbH is a global full-service contract manufacturer with more than 35 years of experience in the development, production and approval of biopharmaceuticals in compliance with international GMP standards (EMA/FDA). Rentschler has nine GMP suites with volumes of 30, 50, 250, 500, 1,000 and 2,500 liters, allowing the production of material for clinical trials (phases I to III) and for market supply and also provides regulatory advice, protein analytics, quality control, and the sterile filling of syringes and injection vials. The company is family-owned and independent and has currently about 650 employees.


Media Contact

Friederike Braun
Director Marketing
Rentschler Biotechnologie GmbH
Phone: +49 7392 701-478
This e-mail address is being protected from spambots. You need JavaScript enabled to view it